Medical/Pharmaceuticals News & Press Release Distribution

Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis

MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ...

2023-10-23 21:30 1153

WAT Medical Donates to the Canadian Red Cross and Peach Arch Hospital

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- WAT Medical Enterprise Ltd. has extended its support to two prominent institutions: the Canadian Red Cross and Peach Arch Hospital, throughmonetary donations. WAT Medical Enterprise Ltd. is a leading ...

2023-10-23 21:00 1166

WAT Medical Donates to the Canadian Red Cross and Peach Arch Hospital

AI Diagnostic Platform Company Noul, unveils the result of Malaria study in Ethiopia and Ghana

* Reaffirming innovation as an AI-based digital microscope while presenting new malaria data at the annual meeting of the ASTMH 2023 * Noul's 'miLab™' showed significantly higher sensitivity than that of microscopy in health centers YONGIN, South Korea, Oct. 23, 2023 /PRNewswire/ -- Noul Co.,...

2023-10-23 21:00 1278

AI Diagnostic Platform Company Noul, unveils the result of Malaria study in Ethiopia and Ghana

VUNO Secures FDA 510(k) Clearance for VUNO Med®-DeepBrain®

SEOUL, South Korea, Oct. 23, 2023 /PRNewswire/ -- VUNO Inc., South Korean medical AI company has received 510(k) clearance from the Food and Drug Administration (FDA) for its AI-powered brain quantification device, VUNO Med®-DeepBrain®.

2023-10-23 21:00 1223

VUNO Secures FDA 510(k) Clearance for VUNO Med®-DeepBrain®

Zhongchao Inc. Launches Breast Cancer Follow-up Visit and Health Management Patient Guide Program on Breast Cancer Awareness Day

SHANGHAI, Oct. 23, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that its Zhongxin platform launched a WeChat mini program of Bre...

2023-10-23 20:00 1149

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. SKY-0515's Phase 1 study will include healthy volunteers before targetingHuntington's patients. Huntington's disease is a fatal neurological disease with no curative therapies. WALTHAM, Ma...

2023-10-23 20:00 1002

Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC

SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest clinical data of it...

2023-10-23 19:56 1111

Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

SHANGHAI, Oct. 23, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces the latest clinical progress of 2 novel drugs including Nectin-4 ADC 9MW2821, as well as the clinical study data to be reported on ESMO 2023. Latest progress...

2023-10-23 18:25 1221

The team from Kelun-Biotech held a meeting with representatives from MSD in Madrid, Spain

CHENGDU, China, Oct. 23, 2023 /PRNewswire/ -- On October 20, 2023, the European Society for Medical Oncology (ESMO) Conference grandly commenced inMadrid, Spain . The ESMO Conference is the most esteemed and influential oncology conference inEurope, and this annual event garners the participation ...

2023-10-23 18:16 1501

JINGHAO MEDICAL's self-fitting OTC hearing aids received FDA 510(k) approval

HONGKONG, SHANGHAI, and BEIJING, Oct. 23, 2023 /PRNewswire/ -- As the first hearing aid manufacturer to be listed in China, JINGHAO MEDICAL has once again taken a historic step. OnSeptember 26, 2023, the self-fitting OTC hearing aid developed and manufactured by JINGHAO MEDICAL officially receive...

2023-10-23 18:01 1125

Global Healthcare Accreditation Welcomes Karin Jay as President of Global Strategy and Announces Renée-Marie Stephano's Transition to CEO

New Leadership Aims to Reinforce GHA's Position as the Foremost Authority in Medical and Well-being Travel Accreditation PALM BEACH GARDENS, Fla., Oct. 23, 2023 /PRNewswire/ -- Global Healthcare Accreditation (GHA), the esteemed authority in accreditation and certification with a specialized foc...

2023-10-23 18:00 1431

Global Healthcare Accreditation Welcomes Karin Jay as President of Global Strategy and Announces Renée-Marie Stephano's Transition to CEO

New Leadership Aims to Reinforce GHA's Position as the Foremost Authority in Medical and Well-being Travel Accreditation PALM BEACH GARDENS, Fla., Oct. 23, 2023 /PRNewswire/ -- Global Healthcare Accreditation (GHA), the esteemed authority in accreditation and certification with a specialized foc...

2023-10-23 18:00 1170

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

SHENZHEN, China, Oct. 23, 2023 /PRNewswire/ -- Mindray (SZSE: 300760), a global leader in medical devices and solutions, introduces high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascu...

2023-10-23 17:53 1481

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer Patients

* Sunvozertinib monotherapy demonstrated superior efficacy and excellent safety in patients in the 1st line setting for advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion (Exon20ins) mutations, achieving a confirmed objective...

2023-10-23 17:34 1027

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

* HMBD-001 is Hummingbird Bioscience's proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and Phase Ib trials inAustralia, targeting multiple solid tumors * The clinical data shows that HMBD-001 is safe and well-tolerated with no dose-limiting toxicities and no severe treatment-re...

2023-10-23 14:23 1414

Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at JSA2023

TOKYO, Oct. 23, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a biotech company specializing in the development of treatments for allergy, asthma, nephrology, dermatology, ophthalmology and other autoimmune diseases, oral presented the phase I data of ...

2023-10-23 12:27 1516

EBR Systems nominated for MTAA Excellence in Medical Technology award

SUNNYVALE, Calif., Oct. 23, 2023 /PRNewswire/ -- EBR Systems, Inc. (ASX:EBR), the developer of the world's only wireless cardiac pacing device for heart failure, is pleased to announce it has been named as a nominee for the 2023 Medical Technology Association ofAustralia ...

2023-10-23 12:26 1429

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

NANJING, China, Oct 22, 2023 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome drug resistance for hard-to-treat solid tumors, announces that clinical data of Ifebemtinib (IN10018), a highly potent and selective oral i...

2023-10-23 08:00 1392

Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO

* The ORR (objective response rate) and the DCR (disease control rate) in the frontline setting of glecirasib (KRAS G12C Inhibitor) in combination with JAB-3312 (SHP2 inhibitor) were 65.5% (38/58) and 100% respectively in all dose groups of advanced non-small cell lung cancer (NSCLC), among whi...

2023-10-22 15:05 1769

Gene Technology Light Up the Future - Opening of the International Conference of Genomics on Eye 2023

SHENYANG, China, Oct. 21, 2023 /PRNewswire/ -- The International Conference of Genomics on Eye 2023 (the "6th ICG Eye") embraced its grand opening in Shenyang on 14th-15th October. The conference, hosted by the Shenyang Municipal People's Government, organized by the Shenyang Bureau of Science a...

2023-10-21 03:12 3313